Obstetrical & Gynecological Survey · 2017 · 22 citations · 0 references
MedicineMaternal HealthObstetricsHigh-risk PregnancyMaternal-fetal MedicinePrenatal DiagnosisMaternal-fetal Immune InteractionsPregnancyPregnancy DiagnosisPregnancy ImmunologyPrenatal Molecular TestingRh AlloimmunizationAntenatal Anti-d ProphylaxisAntenatal Rhd ProphylaxisAnti-d Immunoglobulin ProphylaxisCell-free Fetal Dna TestingProspective Cohort DataRh Alloimmunization ProphylaxisRh Alloimmunization Risk StratificationRh Incompatibility Screening
(Abstracted from BMJ 2016;355:i5789) The risk of maternal alloimmunization due to RhD incompatibility has decreased with use of antenatal and postnatal anti–D immunoglobulin prophylaxis. The discovery of cell-free fetal (cff) DNA in maternal plasma during pregnancy and the feasibility of fetal RhD testing using this source of DNA make it possible to determine fetal RhD type and to restrict the use of antenatal anti–D immunoglobulin to only those RhD-negative women carrying an RhD-positive fetus.